The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 07, 2015

Filed:

Oct. 21, 2011
Applicants:

In-gyu Kim, Daejeon, KR;

Soo Im Choi, Daejeon, KR;

Byung-chul Shin, Daejeon, KR;

Inventors:

In-Gyu Kim, Daejeon, KR;

Soo Im Choi, Daejeon, KR;

Byung-Chul Shin, Daejeon, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); G01N 33/574 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); C12N 15/113 (2010.01); C07K 14/705 (2006.01); C07K 16/30 (2006.01); C12Q 1/68 (2006.01); G01N 33/50 (2006.01); C07K 16/28 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57423 (2013.01); A61K 48/00 (2013.01); A61K 31/7105 (2013.01); A61K 31/713 (2013.01); C12N 15/1138 (2013.01); C12N 2310/14 (2013.01); C07K 14/705 (2013.01); C07K 16/3023 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); C07K 16/28 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition or an anticancer agent for preventing and treating non-small cell lung cancer, containing a substance for regulating the expression or activity of transmembrane 4 L six family member 4 (TM4SF4). More specifically, the present invention relates to a use of a substance for regulating the expression or activity of TM4SF4 as an anticancer drug or an anticancer agent with respect to non-small cell lung cancer, wherein it was ascertained that it is possible to decrease the growth, metastasis, and infiltration of adenocarcinoma cells and radioresistance by decreasing the expression of TM4SF4 in adenocarcinoma among non-small cell lung cancers and to decrease the growth, metastasis, and infiltration of the cells and radioresistance by increasing the expression of TM4SF4 in other non-small cell lung cancers except adenocarcinoma.


Find Patent Forward Citations

Loading…